BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Average Price Target of $441.64 According to Analysts

BeOne Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly bullish: 18 brokerages give BeOne Medicines an average “Buy” rating, with a mean 12-month price target of $441.64. Recent target increases include Barclays at $446 and Citizens JMP at $463.
  • Quarterly results beat expectations: BeOne reported EPS of $3.64 versus the $2.34 consensus estimate, and revenue of $1.89 billion versus analysts’ $1.76 billion forecast.
  • Insiders have been selling: Company insiders sold 135,571 shares worth about $48.5 million over the past three months. The stock opened at $399.70 and has traded between $253.95 and $424.73 over the past year.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have received an average rating of "Buy" from the eighteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $441.64.

Several equities analysts have recently issued reports on the company. Citigroup restated an "outperform" rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Barclays upped their price objective on BeOne Medicines from $415.00 to $446.00 and gave the company an "overweight" rating in a research note on Friday, November 6th. Wolfe Research reaffirmed an "outperform" rating and issued a $370.00 price objective on shares of BeOne Medicines in a research report on Monday, August 10th. Citizens Jmp boosted their target price on BeOne Medicines from $405.00 to $463.00 and gave the stock a "market outperform" rating in a report on Friday, November 6th. Finally, Wells Fargo & Company increased their price target on BeOne Medicines from $400.00 to $435.00 and gave the company an "overweight" rating in a research note on Friday, November 6th.

Check Out Our Latest Analysis on ONC

Insider Buying and Selling

In other news, SVP Chan Lee sold 1,115 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $400.82, for a total value of $446,914.30. Following the completion of the transaction, the senior vice president owned 455 shares of the company's stock, valued at approximately $182,373.10. This represents a 71.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 1,559 shares of the firm's stock in a transaction on Friday, November 6th. The shares were sold at an average price of $405.57, for a total value of $632,283.63. Following the sale, the insider directly owned 880 shares in the company, valued at approximately $356,901.60. This trade represents a 63.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 135,571 shares of company stock worth $48,487,792. 6.19% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of ONC. GAMMA Investing LLC grew its holdings in shares of BeOne Medicines by 39.5% during the third quarter. GAMMA Investing LLC now owns 120 shares of the company's stock valued at $44,000 after buying an additional 34 shares during the last quarter. Mather Group LLC. lifted its position in shares of BeOne Medicines by 192.0% during the 3rd quarter. Mather Group LLC. now owns 73 shares of the company's stock valued at $27,000 after buying an additional 48 shares during the last quarter. Signaturefd LLC raised its position in shares of BeOne Medicines by 13.4% in the third quarter. Signaturefd LLC now owns 414 shares of the company's stock valued at $152,000 after purchasing an additional 49 shares during the period. Steadtrust LLC grew its position in shares of BeOne Medicines by 3.7% during the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company's stock valued at $399,000 after purchasing an additional 50 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in BeOne Medicines by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company's stock worth $110,000 after buying an additional 52 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.

BeOne Medicines Price Performance

NASDAQ ONC opened at $399.70 on Friday. The company has a quick ratio of 3.19, a current ratio of 3.55 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average price of $373.68 and a two-hundred day moving average price of $329.55. The stock has a market capitalization of $43.88 billion, a PE ratio of 50.79 and a beta of 0.63. BeOne Medicines has a 12-month low of $253.95 and a 12-month high of $424.73.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.34 by $1.30. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. As a group, equities analysts predict that BeOne Medicines will post 9.98 earnings per share for the current fiscal year.

About BeOne Medicines

(Get Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

Featured Stories

Analyst Recommendations for BeOne Medicines (NASDAQ:ONC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BeOne Medicines Right Now?

Before you consider BeOne Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.

While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines